Resolvin D2 ELISA Kit

Confirm delete?

Zoom

Cat No: 501120

Assay Kits - Elisa

Resolvin D2 (RvD2) is produced physiologically from the sequential oxygenation of docosahexaenoic acid (DHA) by 15- and 5-lipoxygenases. RvD2 reduces polymorphonuclear leukocyte transendothelial migration, the earliest event in acute inflammation, by ...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Product Overview:
Resolvin D2 (RvD2) is produced physiologically from the sequential oxygenation of docosahexaenoic acid (DHA) by 15- and 5-lipoxygenases. RvD2 reduces polymorphonuclear leukocyte transendothelial migration, the earliest event in acute inflammation, by ~70% at doses as low as 10 pg in the mouse model of peritonitis. In the rat model of burn injury and sepsis, RvD2 restores defective neutrophil motility and dramatically increases survival at doses of 8-10 ng/rat. Resolvins also enhance bacterial clearance by phagocytosis and have been shown to synergistically enhance certain antibiotics. Cayman’s Resolvin D2 ELISA Kit is a competitive assay that can be used for quantification of RvD2. Due to the number and variation of potential sample types, this assay has been validated in Cayman’s ELISA Buffer (Item No. 400060) diluted to 1X (0.1 M potassium phosphate containing 0.1% BSA, 400 mM sodium chloride, 1 mM EDTA, and 0.01% sodium azide), human plasma, and human serum. The assay has a range from 1.6-1,000 pg/ml and a sensitivity (80% B/B0) of approximately 10 pg/ml.

Size	96 strip wells
Shipping	dry ice
Custom Code	3822.19
UNSPSC code	41116104

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.